Private and Public Investments in Biomedical Research
Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to measure these public disclosures, and construct a new data set which corrects for these problems. Our corrected measures suggest that under-reporting of public research support is less of an issue than previously thought.
-
-
Copy CitationMaya M. Durvasula, Lisa Larrimore Ouellette, and Heidi L. Williams, "Private and Public Investments in Biomedical Research," NBER Working Paper 28349 (2021), https://doi.org/10.3386/w28349.
Published Versions
Maya Durvasula & Lisa Larrimore Ouellette & Heidi Williams, 2021. "Private and Public Investments in Biomedical Research," AEA Papers and Proceedings, American Economic Association, vol. 111, pages 341-345, May. citation courtesy of 
Related
Working Groups
More from the NBER
In addition to working papers, the NBER disseminates affiliates’ latest findings through a range of free periodicals — the NBER Reporter, the NBER Digest, the Bulletin on Health, and the Bulletin on Entrepreneurship — as well as online conference reports, video lectures, and interviews.
